Novel topical allogeneic bone-marrow-derived mesenchymal stem cell treatment of hard-to-heal diabetic foot ulcers: a proof of concept study.

ABSTRACT:

Aim

The aim of this study was to investigate safety of treating diabetic foot ulcers with a topically administered mesenchymal stem cell product.

Method

Individuals with diabetes, peripheral neuropathy, toe blood pressure > 39 mmHg and non-infected foot ulcers with duration of four to fifty-two weeks were screened. Participants were treated with a one-time application of a topically applied allogeneic cellular product containing CD362 enriched mesenchymal stem cells suspended in a collagen solution. Participants were subsequently followed for seven months to gather information on adverse event and serious adverse events.

Results/discussion

A total of sixteen individuals were screened, of whom two were included. The included participants incurred a total of seven adver

SUBMITTER: Asko Andersen J 

PROVIDER: S-EPMC9241309 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature